Efficacy, Safety, and Subject Satisfaction After AbobotulinumtoxinA Treatment for Moderate to Severe Glabellar Lines
| Autor: | Corey S. Maas, Gary D. Monheit, Rebecca Down, Rhonda Rand, Leslie Baumann |
|---|---|
| Rok vydání: | 2019 |
| Předmět: |
Moderate to severe
Adult Male medicine.medical_specialty Time Factors Treatment outcome MEDLINE Dermatology Cosmetic Techniques law.invention 030207 dermatology & venereal diseases 03 medical and health sciences Young Adult 0302 clinical medicine Patient satisfaction Randomized controlled trial Double-Blind Method law Medicine Humans Forehead Young adult Botulinum Toxins Type A Aged business.industry General Medicine Middle Aged Skin Aging medicine.anatomical_structure Treatment Outcome Multicenter study Neuromuscular Agents Patient Satisfaction 030220 oncology & carcinogenesis Physical therapy Surgery Female business |
| Zdroj: | Dermatologic surgery : official publication for American Society for Dermatologic Surgery [et al.]. 46(1) |
| ISSN: | 1524-4725 |
| Popis: | The aesthetic use of botulinum toxins is widely accepted in routine treatment of glabellar lines.To strengthen existing efficacy and safety data, and examine subject satisfaction concerning abobotulinumtoxinA (ABO) treatment for moderate to severe glabellar lines.A 150-day prospective, single-dose, multicenter, randomized, parallel-group, placebo-controlled, double-blind study of 300 subjects treated with ABO (50 Units [U]). Response was defined as having no or mild glabellar lines after treatment (primary objective was Day 30 response). Glabellar line severity, onset and duration of effect, satisfaction, treatment emergent adverse events (TEAEs), and treatment-related adverse events (TRAEs) were assessed.Median time to onset of effect was 2 days. Day 30, ABO treatment response was 89% and 85% for investigator and subject assessments, respectively (p.001 vs placebo). At Day 120, 60% of subjects demonstrated ≥1 grade improvement and 45% at Day 150. Subject satisfaction concerning glabellar line appearance was high (93%) at Day 14 and maintained by 35% through Day 150 with ABO treatment. No serious AEs were related to study treatment.Most ABO-treated subjects sustained ≥1 grade glabellar line improvements over 120 days, and satisfaction was maintained by30% of subjects throughout 150 days. ABO was well tolerated. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|